---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/tuberculosis
content_type: therapeutic_choices
document_id: tuberculosis
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:41.417600Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: tuberculosis.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Tuberculosis

### Tuberculosis

|  |
| --- |
| Marie Yan, MD, FRCPCVictoria J. Cook, MD, FRCPCJames C. Johnston, MD, FRCPC |
| Date of Revision: November 21, 2023 |
| Peer Review Date: September 6, 2023 |


#### Introduction

Tuberculosis (TB) is an infectious disease caused by the Mycobacterium tuberculosis (Mtb) complex. In the active form of the disease, the lungs are most commonly affected; however, any organ can be involved and there is potential for person-to-person transmission. For most individuals who acquire Mtb, the infection remains inactive or dormant because the pathogen is contained by host defenses. Dormant TB is not symptomatic or infectious, but could progress to active disease at any time.

TB terminology has changed over time. In the past, the term ‚Äúlatent TB‚Äù was used to indicate dormant Mtb infection without clinically active disease. The preferred terminology is now ‚Äú**TB infection**,‚Äù and ‚Äúactive TB‚Äù is simply referred to as ‚Äú**TB disease**.‚Äù

Although major advances have been made in TB treatment over the years, TB remains a global epidemic and a leading cause of morbidity and mortality. Each year, there are approximately 10 million cases of TB disease and 1.5 million deaths worldwide.‚Äã[^[1]] This chapter addresses the diagnosis and management of patients with TB disease and TB infection. For a general overview of the diagnosis and management of pulmonary TB disease, see Figure 1.

#### Goals of Therapy



#### Investigations

#### History and Physical



|  |  |
| --- | --- |
| Risk factors for Mtb exposure and/or infection‚Äã[5]‚Äã[6]‚Äã[7]‚Äã[8]‚Äã[9] | Known contact with a person with infectious TBCountry of birth/origin or travel to high-incidence regions‚Äã[a]Occupation, e.g., health-care workerIncarcerationSubstandard housing, e.g., underhoused, high household density, poor air quality, inadequate ventilationHigh-risk social environment, e.g., substance use |
| Risk factors for progression to TB disease once infected‚Äã[3]‚Äã[4]‚Äã[10] | Recent Mtb exposure/infection (within 2 y)Documented TST or IGRA conversion within 2 yPredisposing medical conditions, e.g., HIV, organ transplantation, advanced kidney disease, diabetes, certain hematologic and solid malignancies, malnutritionUse of immunosuppressive medications, e.g., systemic corticosteroids, tumour necrosis factor inhibitorsAbnormal chest x-ray compatible with prior TB (e.g., fibronodular pattern)Current tobacco smoking (‚â•1 pack/day) or heavy alcohol use (‚â•3 drinks/day) |
| Risk factors for drug resistance‚Äã[11] | Previous TB treatment or previous drug-resistant disease, especially if DOT was not usedPrevious non-adherence or prior interruptions during TB treatmentHIVResidence in or frequent travel to countries with high prevalence of drug-resistant TB‚Äã[a]Contact with a person with drug-resistant TBYounger age |


directly observed therapy

human immunodeficiency virus

interferon gamma release assay

Mycobacterium tuberculosis

tuberculosis

tuberculin skin test

#### Investigations for TB Disease‚Äã[3]‚Äã[12]



#### Investigations for TB Infection‚Äã[3]‚Äã[12]



| False-Positive Result | False-Negative Result |
| --- | --- |
| Prior BCG vaccination‚Äã[a]Exposure to nontuberculous mycobacteriaInappropriate technique/reading, e.g., recording size of erythema rather than induration | Impaired cell-mediated immunityTB disease or other infection(s)Serious illnessExtremes of ageInappropriate technique/reading, e.g., drawing tuberculin material up into the syringe more than 20 min before administrationStorage and stability issues, e.g., significant exposure of tuberculin to sunlight, cold-chain excursions, expired vials |


bacillus Calmette-Gu√©rin

tuberculosis

tuberculin skin test



#### Therapeutic Choices

#### Public Health Considerations

Notify the local Department of Health or applicable organization for contact tracing. Decisions around contact tracing may vary based on the site(s) of involvement, symptoms, level of infectivity, length of illness and drug resistance.

#### Infection Prevention and Control

All patients with known or suspected pulmonary TB should be either hospitalized in a single-occupancy negative-pressure room with airborne precautions or isolated at home if they can avoid high risk (e.g., young children, immunocompromised) or unexposed contacts. 

The 2022 Canadian TB Standards provide updated conditional recommendations regarding the criteria for de-isolation based on available, albeit poor, evidence.‚Äã[^[22]] A summary of these recommendations is available in Table 3. Notably, sputum smear conversion is no longer an absolute requirement for de-isolation, as evidence suggests that sputum smear status becomes less predictive of infectiousness once patients are established on appropriate therapy. Therefore, in some cases where the patient remains smear-positive even after months of effective treatment, waiting for smear conversion before lifting airborne precautions may cause unnecessary patient harm through protracted isolation without much benefit from the public health perspective.‚Äã[^[22]] Readers are encouraged to review the entire document to ensure a clear understanding of additional caveats.

| Clinical Scenario | Criteria for De-isolation |
| --- | --- |
| Smear-negative, rifampin-susceptible | Clinical evidence of improvementCompleted minimum of 2 weeks of effective therapy |
| Smear-positive, rifampin-susceptible | Clinical evidence of improvementCompleted minimum of 2 weeks of effective therapy3 consecutive negative AFB sputum smears‚Äã[a] |
| Rifampin or multidrug resistant | Consult local TB and public health experts |


acid-fast bacilli

tuberculosis

Proper N95 masks (which filter particles 1 micron in size, have a 95% filter efficiency when tested in the unloaded state and provide a tight facial seal) should be worn by health-care providers when caring for patients with known or suspected infectious TB disease. Surgical masks do not prevent the inhalation of droplet nuclei by others but should be worn by patients to reduce the expulsion of infectious droplets.

All patients with symptoms and/or chest imaging consistent with TB disease should be isolated pending the results of sputum smears for AFB.

#### Nonpharmacologic Choices



#### Pharmacologic Choices

#### Directly Observed Therapy

Patient adherence is a major concern in TB therapy due to the intensive and prolonged nature of treatment, as well as the public health risks posed by the development of drug-resistant TB. To remove barriers to adherence, TB treatment programs should provide patients with access to daily support, individualized to meet their specific needs.

One form of adherence support is directly observed therapy (DOT), which requires health-care professionals or other trained personnel to routinely witness patients swallowing their TB medications.‚Äã[^[26]]‚Äã[^[27]] The decision to implement DOT should be made in conjunction with the patient, with consideration for patient autonomy.

DOT is especially important for regimens involving intermittent therapy as well as for patients who are considered high risk for non-adherence, treatment failure or disease transmission (e.g., drug resistance, HIV infection, social or mental health issues). DOT can be implemented in a variety of settings, including at home, in the community or in a health facility. With recent technological advances, observation through video (VDOT) has emerged as a more cost-effective and convenient option for adherence support.

Successful treatment of TB disease is the joint responsibility of the patient, clinicians, local department of health and government. The delivery of adherence support should be tailored to each patient as part of a comprehensive, patient-centred treatment approach that respects cultural diversity.

#### Tuberculosis Infection

People with TB infection potentially have low numbers of tubercle bacilli in their body; however, unlike people with TB disease, they are asymptomatic and non-infectious. The goal of TB preventive therapy (TPT) is to reduce the risk of progression to active disease. ***Prior to initiating TPT, It is essential to first rule out TB disease through clinical and radiographic assessment.***

In general, people with TB infection have about a 5‚Äì10% risk of developing TB disease over their lifetime.‚Äã[^[28]] However, the risk of progression to active disease is particularly high in certain patient groups.Table 4 presents the interpretation of TST in the diagnosis of TB infection.

| TST Induration | Interpretation‚Äã[a] |
| --- | --- |
| <5 mm | In general, considered negative |
| ‚â•5 mm | Positive in the following populations/scenarios:Recent contact (<2 y) with a person with infectious TB disease Individuals living with HIVStage 4 or 5 chronic kidney disease (with or without dialysis)Prior to receipt of organ transplantation or immunosuppressive therapyPrior to receipt of biologic drugs (e.g., tumour necrosis factor inhibitors) or disease-modifying antirheumatic drugsPrior to receipt of corticosteroids (equivalent to prednisone ‚â•15 mg/day for at least 1 month)Individuals with fibronodular disease on chest radiograph |
| ‚â•10 mm | Positive |


human immunodeficiency virus

tuberculosis

tuberculin skin test

The decision to offer TPT should be individualized, and the potential benefit of treatment must be weighed against the risk of hepatotoxicity and other side effects of therapy. Online tools, such as The Online TST/IGRA Interpreter and PERISKOPE-TB, are available to assist with the interpretation of TST/IGRA results and to help estimate the individual risk-benefit profile of TPT based on a given patient‚Äôs characteristics and test results. The risk of hepatotoxicity is higher in those with pre-existing liver disease and increases with age.‚Äã[^[29]] For patients with risk factors for reactivation (e.g., transplant, chronic kidney disease), age should not preclude treatment, although greater consideration must be made regarding adverse events. Baseline and monthly testing of CBC and liver enzymes are suggested during treatment. For more information, see Antituberculous Drug-Induced Hepatotoxicity.

The recommended first-line TPT options in Canada are 4 months of rifampin or weekly isoniazid (**INH**) and rifapentine for 12 weeks (see Table 5).‚Äã[^[4]]‚Äã[^[30]]‚Äã[^[33]]‚Äã[^[34]] Isoniazid daily for 9 months (9INH) remains an option for patients in whom a rifamycin-containing regimen is contraindicated or not tolerated.‚Äã[^[4]] Rifapentine availability remains limited in Canada and is currently accessed through Health Canada‚Äôs Urgent Public Health Need program.

Consultation with a TB specialist is recommended in the event of contact with a drug-resistant source case or if alternative regimens are considered.

| Place In Therapy | Regimen‚Äã[a] | Frequency‚Äã[b] and Duration‚Äã[c] | Comments |
| --- | --- | --- | --- |
| First-line | RMP | Daily √ó 4 months (120 doses) | Multiple drug-drug interactions; see Table 7 for more information. |
| INH + rifapentine‚Äã[d] | DOT: once weekly √ó 3 months (12 doses) | Only for patients ‚â•2 years of age.Rifapentine availability in Canada is limited.‚Äã[d]Administer vitamin B6 (pyridoxine) 50 mg with each dose to reduce the risk of neuropathy. |  |
| Second-line | INH | Daily √ó 9 months (270 doses) | May be preferable in circumstances where there are drug interactions with RMP.‚Äã[32]Consider vitamin B6 (pyridoxine), starting at 25 mg daily, to reduce the risk of neuropathy. |
| Alternatives | Consult Chapter 6 of the Canadian TB Standards |  |  |


directly observed therapy

isoniazid

rifampin

tuberculosis

#### Tuberculosis Disease

Appropriate treatment of pulmonary TB requires the use of multiple drugs for an extended duration, along with providing patient-centred support to promote and facilitate adherence (see Figure 1). Knowledge of the epidemiology of local resistance is essential to ensure appropriate initial treatment. Empiric therapy should be reviewed and adjusted if necessary when susceptibility results become available (usually 2‚Äì4 wk into treatment). Single drug therapy should never be used for TB disease, nor should a single drug be added to a failing regimen.

Treatment begins with an initial (bactericidal or intensive) phase over the first 2 months to rapidly eliminate most organisms and prevent the emergence of drug resistance. This is followed by a continuation (sterilizing) phase to eradicate any remaining or dormant organisms and prevent relapse by achieving a long-lasting cure. Intermittent therapy in the intensive phase is associated with worse outcomes and should not be used. Intermittent, thrice-weekly treatment for the continuation phase may be offered in select circumstances. Twice-weekly regimens are no longer recommended in Canada.‚Äã[^[26]]‚Äã[^[35]] 

The standard empiric regimen for TB disease consists of isoniazid, rifampin, pyrazinamide and ethambutol. Once the isolate is confirmed to be fully susceptible, Ethambutol may be discontinued, provided that the patient is tolerating, adhering and responding to treatment. For fully susceptible disease, rifampin-based short-course treatment (see Table 6) is the standard of care with a minimum duration of 6 months.‚Äã[^[26]]‚Äã[^[27]]‚Äã[^[35]] For fully susceptible disease, the minimum duration of treatment is 6 months for rifampin-based regimens that include isoniazid and pyrazinamide in the intensive phase of therapy. Longer treatment (minimum 9 months) is recommended for patients with extensive or cavitary pulmonary TB with persistently positive sputum smear or culture at 2 months because of an elevated risk of relapse and treatment failure.‚Äã[^[26]]‚Äã[^[35]]‚Äã[^[36]] The duration of treatment should also be extended to at least 9 months if pyrazinamide is omitted from the regimen.‚Äã[^[26]]‚Äã[^[35]]

Patients should be reassessed at least monthly throughout the course of their therapy. Response to treatment is evaluated through a combination of clinical, radiologic and microbiologic parameters. Follow-up chest imaging should be performed at 2 months and at the end of therapy. Sputum cultures should be collected every 2 weeks until smear conversion is documented (if initially smear positive), then again at 2 months and 1 month prior to the anticipated end of therapy. If the culture remains positive at 2 months, then monthly sputum samples need to be obtained until culture conversion is achieved. Repeat DST is recommended if cultures remain persistently positive after 3 months of treatment.‚Äã[^[26]]‚Äã[^[35]]

Therapeutic drug monitoring (TDM) is not routinely indicated but may be helpful in certain situations. For instance, TDM can guide dosing in patients with liver or kidney dysfunction, drug-resistant disease, or risk of malabsorption (e.g., low body mass index, HIV co-infection).‚Äã[^[26]]‚Äã[^[35]] Currently, routine TDM is not available in Canada, so samples need to be sent to the United States for analysis.

Treatment interruptions are not uncommon and typically occur due to drug intolerance/toxicity. It is generally accepted practice to completely restart from the beginning (i.e., the 4-drug intensive phase) if the cumulative duration of interruption is ‚â•14 days during the initial intensive phase of treatment, or ‚â•2 months during the continuation phase of treatment and <80% of the planned doses have been taken.‚Äã[^[26]]‚Äã[^[35]] Consultation with a TB specialist is suggested when confronted with treatment interruptions, treatment failure or relapse, drug intolerance or adverse effects, or drug resistance.

| Regimen‚Äã[a]‚Äã[b] | Intensive Phase: Frequency‚Äã[c] and Duration‚Äã[d] | Continuation Phase: Frequency‚Äã[c] and Duration‚Äã[d] | Comments |
| --- | --- | --- | --- |
| INH+ RMP + PZA + EMB‚Äã[e] | Option 1: daily‚Äã[f] √ó 2 months | Option 1: INH + RMP daily‚Äã[f] √ó 4‚Äì7 months | **pyridoxine** |
| Option 2: daily‚Äã[f] √ó 2 months | Option 2: INH + RMP thrice weekly √ó 4‚Äì7 months |  |  |
| INH + RMP + EMB | Daily‚Äã[f] √ó 2 months | INH + RMP daily‚Äã[f] (or thrice weekly) √ó 7 months | PZA may be omitted in patients who have a high risk of hepatotoxicity, e.g., >65 years of age. |


directly observed therapy

ethambutol

human immunodeficiency virus

isoniazid

pyrazinamide

rifampin

tuberculosis

#### Drug-Resistant Tuberculosis

Drug-resistant TB is a growing problem and poses considerable challenges to the global effort to eliminate TB. The major risk factors for drug-resistant TB include prior treatment for TB, exposure to a drug-resistant case and prior residence in a region with high rates of drug resistance.‚Äã[^[11]]‚Äã[^[39]]‚Äã[^[40]] DST via growth-based and/or molecular assays are used to determine the extent of drug resistance.

Monoresistance to isoniazid is the most common pattern of resistance in Canada. In contrast, isolated resistance to rifampin is less common and, if detected, should prompt immediate susceptibility testing of other first- and second-line drugs.‚Äã[^[39]]‚Äã[^[40]] Multidrug-resistant TB (MDR-TB) refers to strains that are resistant to both isoniazid and rifampin. Extensively drug-resistant TB (XDR-TB) refers to strains of MDR or rifampin-resistant TB (RR-TB) with additional resistance to fluoroquinolones and at least one other Group A drug, as defined by WHO.‚Äã[^[41]] Drugs belonging to Group A are considered to be the most potent second-line agents and currently include levofloxacin, moxifloxacin, bedaquiline and linezolid.‚Äã[^[11]]‚Äã[^[41]] Pre-XDR-TB is defined as MDR-TB or RR-TB with resistance to any fluoroquinolone but no resistance to other Group A drugs. Further discussion of the treatment for drug-resistant TB is beyond the scope of this chapter.

MDR-TB and XDR-TB are associated with high morbidity and mortality.‚Äã[^[11]]‚Äã[^[39]] ***Further discussion of the treatment for drug-resistant TB is beyond the scope of this chapter. Refer all patients with MDR-TB to a TB specialist with expertise in MDR-TB therapy***. 

#### Antituberculous Drug-Induced Hepatotoxicity

Hepatotoxicity is the most frequent serious adverse event associated with first-line drugs and can occur in relation to pyrazinamide, isoniazid and/or rifampin. Drug-induced liver injury is defined as aminotransferase (AST or ALT) level ‚â•3 times the upper limit of normal in symptomatic patients (e.g., nausea, vomiting, abdominal pain, jaundice) or ‚â•5 times the upper limit of normal in asymptomatic patients.‚Äã[^[26]] In severe cases, fulminant liver failure could develop.

Asymptomatic transaminitis is common in TB therapy, and a decision to stop or withhold treatment must include a plan to rechallenge. If significant or symptomatic hepatotoxicity is detected, withhold all hepatotoxic drugs and consult a local TB specialist to re-establish therapy as quickly as possible. Of the 4 first-line drugs, pyrazinamide is considered to be the most hepatotoxic and therefore, it may be omitted from the regimen in elderly patients and others who are at risk for hepatotoxicity (with longer treatment duration as the trade-off).‚Äã[^[35]]

#### Tuberculosis in Special Populations

#### Pediatric Tuberculosis

When TB is diagnosed in a young child, reverse-contact tracing should be undertaken without delay to identify the infectious source case, typically an adolescent or adult household contact. With rare exceptions (e.g., cavitary or laryngeal tuberculosis), children <5 years of age with TB are not considered infectious. Children <5 years of age with untreated TB are at an increased risk of developing severe forms of TB, such as miliary or meningeal TB; thus, appropriate investigations and treatment need to be initiated promptly upon suspicion of TB, often without microbiologic confirmation.‚Äã[^[16]]‚Äã[^[42]]

Dosing of TB medications in children is determined by weight (mg/kg); note that dosing ranges (per kg) are different than adult dosing ranges for some medications (see Table 7). Regimens recommended in children are similar to those used in adults, although caution is advised with ethambutol use in young children who cannot be assessed reliably for visual toxicity.

Children <5 years of age who are exposed to an infectious case and initially TST-negative may be eligible for primary preventive therapy (also referred to as ‚Äúwindow period prophylaxis‚Äù) with rifampin or isoniazid (or as guided by known drug sensitivities) until a repeat TST is performed 8‚Äì12 weeks after the last break in exposure.‚Äã[^[16]] Consult a TB specialist when exposures include children <6 months of age, as TST results may be difficult to interpret.

#### Extrapulmonary Tuberculosis

The basic principles of management for extrapulmonary TB are similar to pulmonary TB. However, prolonged treatment (‚â•9‚Äì12 months) is recommended for CNS TB (including TB meningitis) and may also be required in certain cases of disseminated or bone and joint TB with high-risk features.‚Äã[^[17]]

In general, adjunctive corticosteroids are routinely indicated for meningeal TB, as they have been shown to decrease short-term mortality.‚Äã[^[26]]‚Äã[^[43]] For pericardial disease, corticosteroids are recommended for HIV-negative patients, but not for HIV-positive patients who are not receiving antiretroviral therapy (ART). At present, no recommendation can be made for HIV-positive patients taking ART; corticosteroids should be considered on a case-by-case basis.‚Äã[^[17]] Adjunctive corticosteroids may also have a role in TB-related adrenal insufficiency, airway compromise secondary to intrathoracic lymphadenopathy and life-threatening disseminated disease.

Always consult a TB specialist when treating a person for CNS TB or TB pericardial disease.

#### HIV Infection

Clinicians should maintain a high index of suspicion because patients with HIV infection who develop TB can be asymptomatic and have other atypical clinical and radiologic findings. Miliary and disseminated disease are more common with lower CD4 counts. Sputum smears are often negative, while blood and stool cultures for mycobacteria may be positive for both TB and nontuberculous mycobacteria.‚Äã[^[13]]‚Äã[^[44]]‚Äã[^[45]]‚Äã[^[46]] 

People living with HIV and TB co-infection should be managed by health-care providers with expertise in these areas. Consultation with a TB or HIV specialist with experience managing HIV-related TB is strongly recommended due to extensive drug interactions and the risk of immune reconstitution inflammatory syndrome (IRIS). For more information on the treatment of HIV, see HIV Infection: Treatment.

#### Choices during Pregnancy and Breastfeeding

#### Active Tuberculosis and Pregnancy

Diagnosis of TB disease in pregnancy may be more difficult as symptoms of fatigue or malaise may be considered normal, and pregnant patients with TB can also be asymptomatic due to pregnancy-related immune suppression.‚Äã[^[47]] Clinical response to TB therapy is similar to the general population, although pregnant and postpartum patients may have higher risks of hepatotoxicity.‚Äã[^[48]]

TB during pregnancy is associated with adverse maternal outcomes (including increased mortality), and infants born to patients with TB disease are at a higher risk for prematurity or low birth weight. Moreover, people with TB disease in pregnancy may transmit Mtb to the baby during gestation (known as congenital TB) or in the postpartum period.‚Äã[^[49]] Therefore, those who are pregnant with suspected TB disease should be thoroughly investigated through standard diagnostic procedures, including sputum specimens and a single posterior-anterior chest x-ray with double shielding (front and back) of the abdomen. TB disease is not an indication for termination of pregnancy, but counselling should be provided by a TB specialist (in collaboration with obstetrics) for patients with drug-resistant disease, as commonly used second-line drugs have potential teratogenic effects. 

#### Management of Tuberculosis Disease in Pregnancy

Treatment of TB disease should not be withheld during pregnancy or the postpartum period, as the risk of untreated TB disease outweighs the risk of adverse events from TB therapy. The preferred initial treatment regimen includes isoniazid, rifampin and ethambutol.‚Äã[^[26]]‚Äã[^[35]] These drugs can cross the placenta, but teratogenic effects have not been demonstrated.‚Äã[^[50]] Pyridoxine (vitamin B6) is also recommended in pregnant patients who are prescribed isoniazid. The use of pyrazinamide in pregnancy has been controversial in North America due to a lack of robust teratogenicity data; however, it is recommended by the WHO and widely used elsewhere in the world.‚Äã[^[27]] Pyrazinamide should be considered in the treatment of pregnant patients with advanced HIV, extensive/disseminated disease or smear-positive pulmonary TB.‚Äã[^[13]]‚Äã[^[26]] If pyrazinamide is excluded from the regimen, the treatment duration should be extended to a minimum of 9 months. 

A patient in labour with infectious TB should wear an appropriate mask, and airborne precautions must be in place until the patient is deemed no longer infectious. If the patient is suspected of having TB disease or known to be infectious in the postpartum period, every effort should be made to prevent further exposure to the newborn. Separation may be required if the patient is considered infectious or has drug-resistant TB, although this should only be done as a last resort considering the associated adverse effects. Separation is not necessary if the patient and the infant are already receiving appropriate therapy for TB disease and prevention, respectively. Priority should be given to appropriate investigation and treatment of the newborn and consultation with a TB specialist is recommended.

#### Tuberculosis Infection in Pregnancy

Pregnancy is not by itself an indication to be screened for TB infection; however, patients with very high risk for progression to disease (e.g., living with HIV) may be screened, since positive test results may warrant treatment during pregnancy. Chest radiographs should still be used in pregnant patients; a single posterior-anterior chest radiograph with double (front and back) shielding of the abdomen is recommended for patients with positive TST or IGRA results, or if symptomatic.

People with childbearing potential who are receiving TPT should be advised to avoid pregnancy. If a person becomes pregnant while on TPT, continuation of the regimen should be considered on a case-by-case basis. In patients without high risk of disease, TPT can be deferred until 3 months postpartum to reduce the risk of hepatotoxicity. If treatment is undertaken, rifampin for 4 months is the preferred regimen.‚Äã[^[4]] In cases where isoniazid therapy is unavoidable during pregnancy or the postpartum period, patients must be monitored carefully for hepatotoxicity and concomitant pyridoxine therapy should be administered.‚Äã[^[26]]

#### Management during Breastfeeding

Breastfeeding is not contraindicated in patients receiving first-line therapy (e.g., isoniazid, rifampin, pyrazinamide, ethambutol). The small concentrations of these drugs in breast milk have not been shown to cause toxicity in infants.‚Äã[^[51]] Breast milk also does not provide adequate serum concentrations for treating an infant. Pyridoxine therapy is recommended for all breastfeeding patients on isoniazid. Breastfed infants of patients taking isoniazid do not require supplemental pyridoxine if the infants are not taking isoniazid themselves.‚Äã[^[16]]‚Äã[^[26]] Consultation with a TB specialist is recommended before breastfeeding while taking second-line therapy.

A discussion of general principles on the use of medications in these special populations can be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding. Other specialized reference sources are also provided in these appendices.

#### Therapeutic Tips



#### Algorithms

![](images/tuberculosis_diamanpultubdis.gif)


**AI Image Description:**
The image is a flowchart outlining the management of suspected pulmonary tuberculosis (TB). It is divided into two main sections: initial evaluation and confirmed TB management.

### Initial Evaluation (Yellow Background)

1. **Symptoms Suggestive of Pulmonary TB**
   - Begin with symptoms that suggest pulmonary TB.

2. **History, Physical, Imaging (Chest X-ray ¬± CT)**
   - Conduct a history, physical examination, and imaging.

3. **Features Concerning for TB on Initial Evaluation**
   - If features are concerning, proceed to obtain microbiologic confirmation.
   - If no evidence of TB, seek an alternate diagnosis.

### Confirmed TB Management (Blue Background)

1. **TB Confirmed**
   - Once TB is confirmed, notify Public Health and continue isolation until criteria for de-isolation are met.

2. **Perform Baseline Testing (Bloodwork, Vision Screening)**
   - Conduct baseline testing, including bloodwork and vision screening.

3. **Consult Expert if New Diagnosis of Co-infection(s), e.g., HIV, Hepatitis**
   - Consult an expert if there is a new diagnosis of co-infections.

4. **Initiate Empiric First-line Treatment**
   - Start empiric first-line treatment, considering potential drug interactions and toxicities.

5. **Drug Susceptibility Testing**
   - Conduct drug susceptibility testing.
   - If TB is drug-resistant, consult a TB specialist.
   - If TB is fully susceptible, continue the first-line regimen.

6. **Ensure Adequate Patient Support, Monitoring, and Follow-up**
   - Ensure patient support, monitoring, and follow-up during and after treatment.

This flowchart provides a structured approach to diagnosing and managing pulmonary TB, emphasizing the importance of isolation, testing, and appropriate treatment.

*AI-generated description for accessibility and content understanding*


computed tomography

human immunodeficiency virus

tuberculosis

#### Drug Table


**Drug Class: Non-Rifamycin Antimycobacterials**


**Drug Class: Rifamycin Antimycobacterials**

| Drug/‚ÄãCost[a] | Dosage[b] | Adverse Effects | Drug Interactions | Comments |
| --- | --- | --- | --- | --- |
| **ethambutol (EMB)** (Etibi) | TB disease:Adults: 15‚Äì20 mg/kg/day (up to 1600 mg/day) PO orDOT: 25‚Äì40 mg/kg (up to 2400 mg/dose) thrice weekly POChildren: 15‚Äì25 mg/kg/day (up to 1600 mg/day) PO or DOT: 30‚Äì50 mg/kg (up to 2400 mg/dose) thrice weekly PO | Ocular toxicity: decreased visual acuity, central scotomata, red-green colour blindness due to retrobulbar neuritis (dose-related; rare at 15 mg/kg/day).Skin rash: Stevens-Johnson syndrome, toxic epidermal necrolysis.Hematologic effects.‚Äã[c]GI upset.‚Äã[d]Neurologic effects: headache, dizziness, confusion, hallucinations. | Decreased levels of EMB with concomitant ingestion of aluminum hydroxide; separate doses by at least 4 h. | First-line agent in TB disease.Assess colour vision and visual acuity at baseline and monitor monthly in patients receiving EMB for longer than 2 months (can use Ishihara-type diagrams available online).Can be used in pregnancy. |
| **isoniazid (INH)** (generics) | TB infection:Adults: 5 mg/kg (up to 300 mg) daily PO orDOT: 15 mg/kg (up to 900 mg) weekly PO (in combination with rifapentine)Children: 10‚Äì15 mg/kg (up to 300 mg) daily PO TB disease: daily therapy recommended over intermittent therapyAdults: 5 mg/kg (up to 300 mg/dose) daily PO orDOT: 10 mg/kg (up to 900 mg/dose)‚Äã[e] thrice weekly POChildren: 10‚Äì15 mg/kg/day (up to 300 mg/day) daily PO or DOT: 20‚Äì30 mg/kg (up to 900 mg/dose) thrice weekly POConsult a specialist in patients with severe liver disease | Asymptomatic increase in hepatic aminotransferases and bilirubin (10‚Äì20%), clinical hepatitis (symptoms typically occur within 2 wk to 6 months), peripheral neuropathy (dose-related).Hematologic effects.‚Äã[c]GI upset.‚Äã[d]Gynecomastia, seizure, drowsiness, drug-induced lupus, toxic encephalopathy, pancreatitis, fever, skin rash, mood changes, lymphadenopathy. | INH increases serum levels of carbamazepine, phenytoin, theophylline.Increased hepatotoxicity of INH with RMP, ethanol, acetaminophen.Cross-hepatotoxicity may occur between drugs that are chemically related, e.g., INH and PZA. Both agents should be avoided if a reaction to one of them occurs. | First-line agent in TB disease.Educate patients on symptoms of hepatitis, e.g., fatigue, flulike symptoms, anorexia, nausea with or without vomiting. Can be used in pregnancy.Consider prescribing pyridoxine to prevent peripheral neuropathy.Best absorbed on an empty stomach; if GI intolerance occurs, may take with a small amount of food. |
| **pyrazinamide (PZA)** (generics) | TB disease:Adults: 20‚Äì25 mg/kg/day (up to 2000 mg/day) PO or DOT: 30‚Äì40 mg/kg (up to 3000 mg/dose) thrice weekly POChildren: 30‚Äì40 mg/kg/day (up to 2000 mg/day) PO or DOT: 60‚Äì80 mg/kg (up to 3000 mg/dose) thrice weekly PO | Hepatotoxicity (rare with 2 months‚Äô therapy), rash, arthralgia, increase in uric acid (acute gout rarely seen), drug fever, GI upset.‚Äã[d]Hematologic effects.‚Äã[c] | Increased PZA levels: concomitant administration of allopurinol through inhibition of xanthine oxidase. | First-line agent in TB disease. |
| **rifabutin** (Mycobutin) | TB disease:Adults: 5 mg/kg/day (up to 300 mg/day) PO | GI upset‚Äã[d], flulike illness, rash, orange discoloration of body fluids (contact lens staining), hepatotoxicity, neutropenia, leukopenia, thrombocytopenia, myalgia, taste perversion, uveitis. | Adjust rifabutin dose when combining with efavirenz or protease inhibitors. Protease inhibitors decrease clearance of rifabutin while efavirenz increases clearance of rifabutin. Do not use with elvitegravir, bictegravir or tenofovir alafenamide.Consult TB/HIV specialist; many interactions with HIV drugs.Decreased serum concentration of drugs due to hepatic enzyme induction, e.g., estrogen-containing contraceptives (oral, patches, rings), anticoagulants, antihyperglycemic agents, immunosuppressants, methadone. Adjust dose of affected drug when a rifamycin is initiated or discontinued. | Preferred rifamycin in HIV-infected patients treated with protease inhibitors or non-nucleoside reverse transcriptase inhibitors.Should not be used first-line in HIV-negative patients unless medication interactions preclude use of RMP. |
| **rifampin (RMP)** (Rofact, generics) | TB infection:Adults: 10 mg/kg/day (up to 600 mg/day) POChildren: 10‚Äì20 mg/kg/day (up to 600 mg/day) POTB disease:‚Äã[52]Adults: 10 mg/kg/day (no maximum) PO or DOT: 10 mg/kg (no maximum) thrice weekly POChildren: 10‚Äì20 mg/kg/day‚Äã[f] (up to 600 mg/day)‚Äã[g] PO or DOT: 10‚Äì20 mg/kg (up to 600 mg/dose)‚Äã[g] thrice weekly POConsult an specialist in patients with severe liver disease | GI upset‚Äã[d], diarrhea, flu-like illness, orange discoloration of body fluids (contact lens staining) and teeth (which may be permanent), urticaria, rash (petechial rash may suggest thrombocytopenia), subclinical disseminated intravascular coagulation, ataxia, confusion, visual disturbances, hepatotoxicity, acute interstitial nephritis.Hematologic effects.‚Äã[c] | Consult TB/HIVspecialist; many interactions with HIV drugs.Decreased serum concentration of drugs due to hepatic enzyme induction, e.g., estrogen-containing contraceptives (oral, patches, rings), anticoagulants, antihyperglycemic agents, immunosuppressants, methadone. Adjust dose of affected drug when a rifamycin is initiated or discontinued.Avoid use with doravirine, etravirine, elvitegravir, nevirapine, protease inhibitors, rilpivirine and tenofovir alafenamide.Increase dose of integrase inhibitors or maraviroc if used concomitantly with RMP. | First-line agent in TB disease.Can be used in pregnancy.Frequently implicated in drug interactions.Best absorbed on an empty stomach; if GI intolerance occurs, may take with a small amount of food.Note: The WHO recommends no dosing ceiling in TB disease treatment (i.e., dosing should continue at 10 mg/kg in adults>60 kg), although there is limited evidence to support this approach. Therapeutic drug monitoring is suggested if dosing exceeds 600 mg/day. |
| **rifapentine** | TB infection (in combination with INH):‚Äã[34]Children and adults: weight-based dosing, once weekly PO. Can only be used in children ‚â•2 years of age10‚Äì14 kg: 300 mg/dose>14‚Äì25 kg: 450 mg/dose>25‚Äì32 kg: 600 mg/dose>32‚Äì50 kg: 750 mg/dose>50 kg: 900 mg/dose | GI upset‚Äã[d], flu‚Äìlike illness, orange discoloration of body fluids (contact lens staining), hepatotoxicity, anemia, leukopenia. | Consult TB/HIVspecialist; many interactions with HIV drugs.Decreased serum concentration of drugs due to hepatic enzyme induction, e.g., estrogen-containing contraceptives (oral, patches, rings), anticoagulants, antihyperglycemic agents, immunosuppressants, methadone. Adjust dose of affected drug when a rifamycin is initiated or discontinued.May be safe to use with dolutegravir. More data needed regarding boosted protease inhibitors and tenofovir. | Use in Canada is limited as this drug is available only through Health Canada‚Äôs Urgent Public Health Need program. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

directly observed treatment

ethambutol

gastrointestinal

human immunodeficiency virus

Infectious Diseases Society of America/American Thoracic Society

isoniazid

pyrazinamide

rifampin

tuberculosis

World Health Organization

#### Suggested Readings

**Guidelines:**

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine *Canadian tuberculosis standards 8th edition: 2022* [internet]. 2022. Available from:www.tandfonline.com/doi/epdf/10.1080/24745332.2022.2033055?needAccess=true.

Lewinsohn DM, Leonard MK, LoBue PA et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. *Clin Infect Dis* 2017;64(2):e1-e33.

Nahid P, Dorman SE, Alipanah N et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63(7):e147-e195.

**Journal Articles:**

Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and metaanalysis. *Clin Infect Dis* 2017;64(9):1211-20.

Menzies D, Adjobimey M, Ruslami R et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. *N Engl J Med* 2018;379(5):440-53.

Romanowski K, Balshaw RF, Benedetti A et al. Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. *Thorax* 2019;74(3):291-7.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/tuberculosis](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/tuberculosis)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *tuberculosis*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/tuberculosis


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/tuberculosis)*
